RxDoctor Payments Data

Michael Seawell, MD

Interventional Cardiology · Edinburg, TXNPI 1508041534

Payments from drug & device makers

$199,629in general payments, 2019–2025

Across 175 payments — averaging $1140.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$186K
  • Shockwave Medical, Inc$7K
  • Abbott$2K
  • Penumbra, Inc.$829
  • Boston Scientific$601
  • Recor Medical Inc$500
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$6544%
  • Speaking & faculty fees$6,60040%
  • Travel & lodging$1,86811%
  • Food & beverage$7,30644%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$199,629 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$81,797
Medicare patients
358
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$205,479
XareltoRivaroxaban165$186,399
EntrestoSacubitril/Valsartan127$157,399
FarxigaDapagliflozin Propanediol52$52,693
BrilintaTicagrelor43$25,521
JardianceEmpagliflozin24$24,090
Metoprolol Succinate471$8,952
Nifedipine ErNifedipine191$5,658
Olmesartan Medoxomil156$2,701
Atorvastatin Calcium241$2,543
Losartan Potassium203$2,371
ClopidogrelClopidogrel Bisulfate155$1,916
Amlodipine Besylate309$1,738
Rosuvastatin Calcium116$1,563
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide33$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$205,479196 claims
Johnson & JohnsonXarelto$486$186,399165 claims
NovartisEntresto$71$157,399127 claims
AstraZenecaFarxiga, Brilinta$49$78,21395 claims
Boehringer IngelheimJardiance$201$24,09024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →